Globus Medical, Inc. (GMED)
USD 81.78
(-1.97%)
USD 81.78
(-1.97%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 418.23 Million USD | 27.79% |
| 2022 | 304.5 Million USD | 8.57% |
| 2021 | 250.27 Million USD | 58.24% |
| 2020 | 178.34 Million USD | -20.57% |
| 2019 | 242.67 Million USD | 1.72% |
| 2018 | 218.51 Million USD | 6.4% |
| 2017 | 208.7 Million USD | 4.73% |
| 2016 | 201.89 Million USD | 16.75% |
| 2015 | 188.39 Million USD | 1.35% |
| 2014 | 164.84 Million USD | 2.55% |
| 2013 | 145.38 Million USD | 27.3% |
| 2012 | 132.76 Million USD | 12.01% |
| 2011 | 113.89 Million USD | 8.11% |
| 2010 | 102.93 Million USD | 9.35% |
| 2009 | 95.28 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 97.38 Million USD | -7.52% |
| 2024 Q3 | 48.09 Million USD | 2.15% |
| 2024 Q2 | 127.71 Million USD | -18.02% |
| 2023 Q4 | 93.03 Million USD | -20.19% |
| 2023 FY | - USD | 27.79% |
| 2023 Q1 | 77.02 Million USD | 7.83% |
| 2023 Q2 | 90.76 Million USD | 17.85% |
| 2023 Q3 | 116.57 Million USD | 28.43% |
| 2022 Q2 | 83.6 Million USD | 22.58% |
| 2022 Q4 | 71.42 Million USD | -8.64% |
| 2022 Q3 | 78.18 Million USD | -6.48% |
| 2022 FY | - USD | 8.57% |
| 2022 Q1 | 68.2 Million USD | 74.95% |
| 2021 Q2 | 92.53 Million USD | 27.91% |
| 2021 Q4 | 38.98 Million USD | -46.53% |
| 2021 FY | - USD | 58.24% |
| 2021 Q1 | 72.34 Million USD | -8.26% |
| 2021 Q3 | 72.91 Million USD | -21.21% |
| 2020 Q1 | 44.58 Million USD | -19.44% |
| 2020 FY | - USD | -20.57% |
| 2020 Q4 | 78.86 Million USD | 38.69% |
| 2020 Q3 | 56.86 Million USD | 680.93% |
| 2020 Q2 | -9.78 Million USD | -121.96% |
| 2019 Q3 | 59.85 Million USD | 7.18% |
| 2019 FY | - USD | 1.72% |
| 2019 Q1 | 50.13 Million USD | -14.81% |
| 2019 Q2 | 55.85 Million USD | 11.4% |
| 2019 Q4 | 55.33 Million USD | -7.55% |
| 2018 FY | - USD | 6.4% |
| 2018 Q4 | 58.85 Million USD | 18.9% |
| 2018 Q2 | 45.88 Million USD | -17.34% |
| 2018 Q1 | 55.5 Million USD | 8.8% |
| 2018 Q3 | 49.5 Million USD | 7.89% |
| 2017 Q1 | 53.07 Million USD | -1.92% |
| 2017 Q2 | 40.9 Million USD | -22.94% |
| 2017 Q3 | 49.59 Million USD | 21.26% |
| 2017 FY | - USD | 4.73% |
| 2017 Q4 | 51.01 Million USD | 2.87% |
| 2016 Q1 | 49.52 Million USD | 26.96% |
| 2016 Q3 | 47.87 Million USD | -6.23% |
| 2016 Q2 | 51.05 Million USD | 3.08% |
| 2016 Q4 | 54.11 Million USD | 13.04% |
| 2016 FY | - USD | 16.75% |
| 2015 Q1 | 44.27 Million USD | -9.41% |
| 2015 Q2 | 37.77 Million USD | -14.68% |
| 2015 Q3 | 46.81 Million USD | 23.93% |
| 2015 Q4 | 39.01 Million USD | -16.68% |
| 2015 FY | - USD | 1.35% |
| 2014 Q2 | 39.57 Million USD | -7.12% |
| 2014 Q4 | 48.87 Million USD | 21.02% |
| 2014 Q3 | 40.38 Million USD | 2.05% |
| 2014 Q1 | 42.6 Million USD | -7.79% |
| 2014 FY | - USD | 2.55% |
| 2013 FY | - USD | 27.3% |
| 2013 Q3 | 34.56 Million USD | -34.14% |
| 2013 Q4 | 46.2 Million USD | 33.7% |
| 2013 Q1 | 33.94 Million USD | 16.48% |
| 2013 Q2 | 52.47 Million USD | 54.6% |
| 2012 Q1 | 32.82 Million USD | 5.2% |
| 2012 FY | - USD | 12.01% |
| 2012 Q4 | 29.14 Million USD | -8.12% |
| 2012 Q3 | 31.71 Million USD | -10.34% |
| 2012 Q2 | 35.37 Million USD | 7.76% |
| 2011 Q4 | 31.2 Million USD | 0.58% |
| 2011 Q2 | 27.88 Million USD | 2.7% |
| 2011 FY | - USD | 8.11% |
| 2011 Q1 | 27.15 Million USD | 0.0% |
| 2011 Q3 | 31.02 Million USD | 11.25% |
| 2010 FY | - USD | 9.35% |
| 2009 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 96.003% |
| Allurion Technologies Inc. | -69.03 Million USD | 705.871% |
| Artivion, Inc. | 38.14 Million USD | -996.531% |
| Avanos Medical, Inc. | 53.2 Million USD | -686.164% |
| Butterfly Network, Inc. | -124.84 Million USD | 435.009% |
| Butterfly Network, Inc. | -124.84 Million USD | 435.009% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 168.759% |
| Boston Scientific Corporation | 3.45 Billion USD | 87.888% |
| Perspective Therapeutics, Inc. | -14.83 Million USD | 2918.702% |
| CONMED Corporation | 182.18 Million USD | -129.567% |
| Edwards Lifesciences Corporation | 1.76 Billion USD | 76.339% |
| Paragon 28, Inc. | -36.61 Million USD | 1242.293% |
| Glaukos Corporation | -82.11 Million USD | 609.327% |
| Inspire Medical Systems, Inc. | -17.06 Million USD | 2551.577% |
| Integer Holdings Corporation | 282.05 Million USD | -48.281% |
| Medtronic plc | 9.05 Billion USD | 95.382% |
| Nevro Corp. | -78.31 Million USD | 634.081% |
| Owlet, Inc. | -27.48 Million USD | 1621.478% |
| Penumbra, Inc. | 111.99 Million USD | -273.441% |
| Vicarious Surgical Inc. | -69.19 Million USD | 704.461% |
| Smith & Nephew plc | 979 Million USD | 57.279% |
| Sonendo, Inc. | -54.76 Million USD | 863.656% |
| STERIS plc | 1.41 Billion USD | 70.388% |
| Stryker Corporation | 5.16 Billion USD | 91.895% |
| Vapotherm, Inc. | -34.35 Million USD | 1317.333% |
| Zimmer Biomet Holdings, Inc. | 2.44 Billion USD | 82.921% |